ABL1 and leukemia: When comparing the targets between Dasatinib and imatinib/nilotinib, there are six common target kinases: Kit, PDGFR, ABL1, DDR1, ARG (ABL2), and the fusion kinase present only in certain leukemias, BCR-Abl (Hantschel et al., 2008) (Figure 1C).